258 related articles for article (PubMed ID: 21134979)
21. New agents in acute myeloid leukemia: beyond cytarabine and anthracyclines.
Fathi AT; Karp JE
Curr Oncol Rep; 2009 Sep; 11(5):346-52. PubMed ID: 19679009
[TBL] [Abstract][Full Text] [Related]
22. The cyclin-dependent kinase inhibitor SNS-032 has single agent activity in AML cells and is highly synergistic with cytarabine.
Walsby E; Lazenby M; Pepper C; Burnett AK
Leukemia; 2011 Mar; 25(3):411-9. PubMed ID: 21212792
[TBL] [Abstract][Full Text] [Related]
23. Action of SN 28049, a new DNA binding topoisomerase II-directed antitumour drug: comparison with doxorubicin and etoposide.
Drummond CJ; Finlay GJ; Broome L; Marshall ES; Richardson E; Baguley BC
Invest New Drugs; 2011 Oct; 29(5):1102-10. PubMed ID: 20567995
[TBL] [Abstract][Full Text] [Related]
24. Targeting Topoisomerase II Activity in NSCLC with 9-Aminoacridine Derivatives.
Ferguson DM; Jacobson BA; Jay-Dixon J; Patel MR; Kratzke RA; Raza A
Anticancer Res; 2015 Oct; 35(10):5211-7. PubMed ID: 26408679
[TBL] [Abstract][Full Text] [Related]
25. XPO1 Inhibition using Selinexor Synergizes with Chemotherapy in Acute Myeloid Leukemia by Targeting DNA Repair and Restoring Topoisomerase IIα to the Nucleus.
Ranganathan P; Kashyap T; Yu X; Meng X; Lai TH; McNeil B; Bhatnagar B; Shacham S; Kauffman M; Dorrance AM; Blum W; Sampath D; Landesman Y; Garzon R
Clin Cancer Res; 2016 Dec; 22(24):6142-6152. PubMed ID: 27358488
[TBL] [Abstract][Full Text] [Related]
26. Molecular effects of topoisomerase II inhibitors in AML cell lines: correlation of apoptosis with topoisomerase II activity but not with DNA damage.
Gieseler F; Bauer E; Nuessler V; Clark M; Valsamas S
Leukemia; 1999 Nov; 13(11):1859-63. PubMed ID: 10557063
[TBL] [Abstract][Full Text] [Related]
27. (S)-Erypoegin K, an isoflavone isolated from Erythrina poeppigiana, is a novel inhibitor of topoisomerase IIα: Induction of G2 phase arrest in human gastric cancer cells.
Hikita K; Yamakage Y; Okunaga H; Motoyama Y; Matsuyama H; Matsuoka K; Murata T; Nakayoshi T; Oda A; Kato K; Tanaka H; Asao N; Dan S; Kaneda N
Bioorg Med Chem; 2021 Jan; 30():115904. PubMed ID: 33341500
[TBL] [Abstract][Full Text] [Related]
28. A Kinase Inhibitor with Anti-Pim Kinase Activity is a Potent and Selective Cytotoxic Agent Toward Acute Myeloid Leukemia.
Bjørnstad R; Aesoy R; Bruserud Ø; Brenner AK; Giraud F; Dowling TH; Gausdal G; Moreau P; Døskeland SO; Anizon F; Herfindal L
Mol Cancer Ther; 2019 Mar; 18(3):567-578. PubMed ID: 30679386
[TBL] [Abstract][Full Text] [Related]
29. Topoisomerase IIalpha expression in acute myeloid leukaemia cells that survive after exposure to daunorubicin or ara-C.
Tina E; Prenkert M; Höglund M; Paul C; Tidefelt U
Oncol Rep; 2009 Dec; 22(6):1527-31. PubMed ID: 19885609
[TBL] [Abstract][Full Text] [Related]
30. Targeting acute myeloid leukemia with TP53-independent vosaroxin.
Benton CB; Ravandi F
Future Oncol; 2017 Jan; 13(2):125-133. PubMed ID: 27615555
[TBL] [Abstract][Full Text] [Related]
31. Enhanced Response of Acute Monocytic Leukemia Cells to Low-dose Cytarabine by 1,25-dihydroxyvitamin D3.
Guo H; Lin SY; Ren WX; Lei Q; Chen ZC; Zhang L; Li QB
Curr Med Sci; 2018 Feb; 38(1):35-42. PubMed ID: 30074149
[TBL] [Abstract][Full Text] [Related]
32. MK-2206 induces apoptosis of AML cells and enhances the cytotoxicity of cytarabine.
Lu JW; Lin YM; Lai YL; Chen CY; Hu CY; Tien HF; Ou DL; Lin LI
Med Oncol; 2015 Jul; 32(7):206. PubMed ID: 26087957
[TBL] [Abstract][Full Text] [Related]
33. G226, a new epipolythiodioxopiperazine derivative, triggers DNA damage and apoptosis in human cancer cells in vitro via ROS generation.
He PX; Zhang J; Che YS; He QJ; Chen Y; Ding J
Acta Pharmacol Sin; 2014 Dec; 35(12):1546-55. PubMed ID: 25468822
[TBL] [Abstract][Full Text] [Related]
34. New fused pyrimidine derivatives with anticancer activity: Synthesis, topoisomerase II inhibition, apoptotic inducing activity and molecular modeling study.
Nemr MTM; AboulMagd AM
Bioorg Chem; 2020 Oct; 103():104134. PubMed ID: 32750610
[TBL] [Abstract][Full Text] [Related]
35. Homologous recombination repair is essential for repair of vosaroxin-induced DNA double-strand breaks.
Hawtin RE; Stockett DE; Wong OK; Lundin C; Helleday T; Fox JA
Oncotarget; 2010 Nov; 1(7):606-619. PubMed ID: 21317456
[TBL] [Abstract][Full Text] [Related]
36. Antitumor Effect of
Labbozzetta M; Poma P; Occhipinti C; Sajeva M; Notarbartolo M
Molecules; 2022 Jun; 27(13):. PubMed ID: 35807446
[TBL] [Abstract][Full Text] [Related]
37. Proteasomal inhibition potentiates drugs targeting DNA topoisomerase II.
Lee KC; Bramley RL; Cowell IG; Jackson GH; Austin CA
Biochem Pharmacol; 2016 Mar; 103():29-39. PubMed ID: 26794000
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of topoisomerase IIalpha and G2 cell cycle arrest by NK314, a novel benzo[c]phenanthridine currently in clinical trials.
Guo L; Liu X; Nishikawa K; Plunkett W
Mol Cancer Ther; 2007 May; 6(5):1501-8. PubMed ID: 17513599
[TBL] [Abstract][Full Text] [Related]
39. HU-331 is a catalytic inhibitor of topoisomerase IIα.
Regal KM; Mercer SL; Deweese JE
Chem Res Toxicol; 2014 Dec; 27(12):2044-51. PubMed ID: 25409338
[TBL] [Abstract][Full Text] [Related]
40. Discovery and antiproliferative evaluation of new quinoxalines as potential DNA intercalators and topoisomerase II inhibitors.
Eissa IH; Metwaly AM; Belal A; Mehany ABM; Ayyad RR; El-Adl K; Mahdy HA; Taghour MS; El-Gamal KMA; El-Sawah ME; Elmetwally SA; Elhendawy MA; Radwan MM; ElSohly MA
Arch Pharm (Weinheim); 2019 Nov; 352(11):e1900123. PubMed ID: 31463953
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]